Paul Anthony Williams - 01 Jul 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: SVP, Products Business
Issuer ticker: EBS
Reported as of: 01 Jul 2026
Net transaction value: -$25,200
SEC form: 4
Accepted by SEC: 02 Jul 2026, 12:57:23 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Paul Anthony Williams filed Form 4 for Emergent BioSolutions Inc. (EBS) on 02 Jul 2026.

Key facts

This page summarizes Paul Anthony Williams's Form 4 filing for Emergent BioSolutions Inc. (EBS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 12:57.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: -$25,200.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001961994 Primary reporting owner

Williams Paul Anthony

Relationship: SVP, Products Business
Address: 300 PROFESSIONAL DRIVE, GAITHERSBURG
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Sale

Transaction value: $25,200
Shares: -3,000
Change %: -1.9%
Price: $8.40
Shares after: 159,098
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.